Disease · MONDO_0008575
Comparisons in its trials315
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 315
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Proactive Group vs Reactive Group: serious adverse events | 16 of 649 | 6 of 649 | 1,298 | NCT00632411 | Trial comparisons |
| Proactive Group vs Reactive Group: Continuous Abstinence | 173 of 521 | 136 of 529 | 1,050 | NCT00632411 | Trial comparisons |
| Intervention vs Control: Number of Participants With Self-reported Tobacco Abstinence in Past 7 Days | 95 of 482 | 79 of 352 | 834 | NCT03717051 | Trial comparisons |
| Intervention vs Control: Number of Participants With Self-reported Use of NRT in Past Week/Month | 92 of 482 | 86 of 352 | 834 | NCT03717051 | Trial comparisons |
| Intervention vs Control: Number of Participants With Self-reported Quit Attempt | 214 of 482 | 153 of 352 | 834 | NCT03717051 | Trial comparisons |
| Intervention vs Control: Number of Participants With Self-reported Tobacco Abstinence in Past 7 Days | 104 of 482 | 92 of 352 | 834 | NCT03717051 | Trial comparisons |
| Intervention vs Control: Number of Participants Who Enroll in Any Smoking Cessation Service in Hong Kong | 156 of 482 | 158 of 352 | 834 | NCT03717051 | Trial comparisons |
| Intervention vs Control: Number of Participants With Self-reported Quit Attempt | 300 of 482 | 243 of 352 | 834 | NCT03717051 | Trial comparisons |
| Intervention vs Control: Number of Participants Who Enroll in Any Smoking Cessation Service in Hong Kong | 247 of 482 | 213 of 352 | 834 | NCT03717051 | Trial comparisons |
| Intervention vs Control: Biochemically Validated Abstinence at 6-month Follow-up | 22 of 482 | 10 of 352 | 834 | NCT03717051 | Trial comparisons |
| Intervention vs Control: Number of Participants With Self-reported Tobacco Abstinence in Past 30 Days | 68 of 482 | 52 of 352 | 834 | NCT03717051 | Trial comparisons |
| Intervention vs Control: Number of Participants With Self-reported Tobacco Abstinence in Past 30 Days | 93 of 482 | 77 of 352 | 834 | NCT03717051 | Trial comparisons |
| Intervention vs Control: Number of Participants With Self-reported Use of NRT in Past Week/Month | 192 of 482 | 121 of 352 | 834 | NCT03717051 | Trial comparisons |
| Intervention vs Control: deaths from any cause | 0 of 482 | 0 of 352 | 834 | NCT03717051 | Trial comparisons |
| Intervention vs Control: serious adverse events | 0 of 482 | 0 of 352 | 834 | NCT03717051 | Trial comparisons |
| Transdermal Nicotine vs Nicotine Nasal Spray: Continuous Abstinence at End of Treatment (Self-report)(Defined as the Number of Consecutive Days Without Smoking a Cigarette for Each Subject) | 83 of 344 | 75 of 330 | 674 | NCT00326781 | Trial comparisons |
| Transdermal Nicotine vs Nicotine Nasal Spray: Verified 7-day Point Prevalence Abstinence at End Of Treatment. | 112 of 344 | 95 of 330 | 674 | NCT00326781 | Trial comparisons |
| Transdermal Nicotine vs Nicotine Nasal Spray: serious adverse events | 0 of 344 | 0 of 330 | 674 | NCT00326781 | Trial comparisons |
| Varenicline vs Placebo: serious adverse events | 6 of 486 | 1 of 165 | 651 | NCT00691483 | Trial comparisons |
| Arm I vs Arm II: 24-hour Point Prevalence Abstinence at the 6-month Follow up | 50 of 321 | 35 of 321 | 642 | NCT00365508 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0008575/comparisons